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Background
Thailand, site of numerous HIV chemoprophylaxis trials
and the world's only ongoing phase-3 HIV vaccine trial,
may be an early adopter of HIV vaccines. We assessed
acceptability of preventive HIV vaccines and behavioral
risk compensation among individuals from high-risk
communities likely to be targeted for initial vaccine roll-
out.
Methods
We developed a structured questionnaire based on our
formative qualitative research (n = 30) among vulnerable
community stakeholders, HIV physicians and HIV pre-
vention experts in Thailand. The 30-minute questionnaire
was programmed on laptop computers in Thai and
administered by trained interviewers. Participants were
recruited using venue-based sampling from sex venues
and community-based organizations serving men who
have sex with men (MSM), male sex workers and trans-
genders in Bangkok and Chiang Mai. We assessed HIV
vaccine acceptability using conjoint analysis and a frac-
tional factorial experimental design, and risk behavior
intentions in response to HIV vaccine uptake.
Results
Participants (n = 260) were MSM (84.2%) and transgen-
ders (15.8%); mean age = 26.7 (SD = 5.6) years. Most
(58.1%) engaged in paid sex; 20.0% reported STI diagno-
sis (past year); with an average of 11.3 male partners (past
3 months). HIV vaccine acceptability ranged from 73.8
(SD = 29.6) to 31.9 (SD = 33.6) on a 100-point scale;
mean = 58.5 (SD = 17.3). Vaccine-induced seropositivity
(VISP) had the greatest impact on acceptability (18.5; p <
0.001), followed by efficacy (15.7; p < 0.001), side effects
(9.4; p < 0.001), duration (5.0; p < 0.001), out-of-pocket
cost (3.6; p = 0.005) and social saturation (i.e., percentage
of the population already vaccinated; 2.5; p = 0.02). Over
one-third (34.6%) reported intentions to increase sexual
risk behaviors in response to HIV vaccine uptake.
Conclusion
Findings support the development of interventions to
mitigate the impact of VISP, increase acceptability of par-
tially efficacious vaccines and foster understanding about
possible side effects, which may facilitate HIV vaccine
uptake among high-risk MSM and transgenders in Thai-
land. Behavioral interventions to decrease risk compensa-
tion will be a crucial component of combination
prevention.
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